Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

MULTIPLE MYELOMA, GAMMOPATHIES

Molecular profiling and risk stratification in solitary bone plasmacytoma

Leukemia volume 39, pages 2568–2572 (2025)Cite this article

Subjects

Access through your institution
Buy or subscribe

Solitary bone plasmacytoma (SBP), a rare form of tumoral plasma cell, is characterized by a single bone lesion, with histological confirmation of a homogenous infiltrate of tumoral plasma cells (PC). Stringent criteria are required to confirm that the lesion is unique, including bone marrow (BM) exploration, whole body (WB) magnetic resonance imaging (MRI) and/or positron emission tomography (PET)-tomodensitometry (TDM) [1]. There is a lack of consensus for the treatment of SBP [2,3,4], the evolution of which is heterogeneous, from prolonged remission to progression toward symptomatic MM. The molecular data used for MM prognosis is lacking in SBP, although it could be valuable to improve patient management.

The study reported here attempted at demonstrating the feasibility and prognostic impact of next generation sequencing (NGS) of DNA extracted from formalin-fixed paraffin-embedded (FFPE) or frozen diagnostic bone biopsies of SBP, allowing for the identification of translocations, copy number alterations (CNA) and mutations.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Progression-free survival (PFS) according patient status.

Data availability

Data from this study can be made available upon request from the corresponding author.

References

  1. Caers J, Paiva B, Zamagni E, Leleu X, Bladé J, Kristinsson SY, et al. Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel. J Hematol Oncol. 2018;11:10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Tsang RW, Campbell BA, Goda JS, Kelsey CR, Kirova YM, Parikh RR, et al. Radiation therapy for solitary plasmacytoma and multiple myeloma: guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2018;101:794–808.

    Article  PubMed  Google Scholar 

  3. Le Ray E, Belin L, Plancher C, Anract P, Babinet A, Dumaine V, et al. Our experience of solitary plasmacytoma of the bone: improved PFS with a short-course treatment by IMiDs or proteasome inhibitors combined with intensity-modulated radiotherapy. Leuk Lymphoma. 2018;59:1756–8.

    Article  PubMed  Google Scholar 

  4. Ascione S, Harel S, Besson FL, Belkhir R, Henry J, Royer B, et al. Chemotherapy in solitary bone plasmacytoma to prevent evolution to multiple myeloma. Haematologica. 2023;108:3160–4.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–48.

    Article  PubMed  Google Scholar 

  6. Fermand JP, Bridoux F, Dispenzieri A, Jaccard A, Kyle RA, Leung N, et al. Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications. Blood. 2018;132:1478–85.

    Article  CAS  PubMed  Google Scholar 

  7. Bolli N, Li Y, Sathiaseelan V, Raine K, Jones D, Ganly P, et al. A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma. Blood Cancer J. 2016;6:e467.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Perrot A, Lauwers-Cances V, Tournay E, Hulin C, Chretien ML, Royer B, et al. Development and validation of a cytogenetic prognostic index predicting survival in multiple myeloma. J Clin Oncol. 2019;37:1657–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. D’Agostino M, Cairns DA, Lahuerta JJ, Wester R, Bertsch U, Waage A, et al. Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project. J Clin Oncol. 2022;40:3406–18.

    Article  PubMed  Google Scholar 

  10. Avet-Loiseau H, Davies F, Samur M, Corre J, D'Agostino M, Kaiser M, et al. International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma. J. Clin. Oncol. 2025;43. https://doi.org/10.1200/JCO-24-01893. Online ahead of print.

  11. Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–46.

    Article  PubMed  Google Scholar 

  12. Zamagni E, Nanni C, Dozza L, Carlier T, Bailly C, Tacchetti P, et al. Standardization of 18F-FDG-PET/CT according to Deauville criteria for metabolic complete response definition in newly diagnosed multiple myeloma. J Clin Oncol. 2021;39:116–25.

    Article  CAS  PubMed  Google Scholar 

  13. Yadav U, Kumar SK, Baughn LB, Dispenzieri A, Greipp P, Ketterling R, et al. Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas. Blood. 2023;142:1871–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Shah V, Johnson DC, Sherborne AL, Ellis S, Aldridge FM, Howard-Reeves J, et al. Subclonal TP53 copy number is associated with prognosis in multiple myeloma. Blood. 2018;132:2465–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Schavgoulidze A, Corre J, Samur MK, Mazzotti C, Pavageau L, Perrot A, et al. RAS/RAF landscape in monoclonal plasma cell conditions. Blood. 2024;144:201–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

Medical writing for this manuscript was assisted by MPIYP (MC Béné), Paris, France. The authors also thank Dr Marc Polivka, Department of Pathology, Lariboisière hospital, AP-HP, Nord-University Paris Centre, Paris, France.

Author information

Author notes

  1. Bertrand Arnulf

    Present address: Université Paris centre, Paris, France

  2. These authors contributed equally: Stéphanie Harel, Raphaele Seror.

Authors and Affiliations

  1. Department of Pathology, GHU Paris Centre - Cochin-, AP-HP, Paris, France

    Barbara Burroni, Diane Damotte, Virginie Audard & Frédérique Larousserie

  2. Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université Paris Cité, Team Inflammation, Complement and Cancer, Paris, France

    Barbara Burroni, Diane Damotte & Yoan Velut

  3. Department of Immuno Hematology, GHU Paris-Nord - Saint-Louis -AP-HP, Paris, France

    Stéphanie Harel, Alexis Talbot, Bruno Royer & Bertrand Arnulf

  4. Department of Rheumatology, GHU Paris Saclay – Kremlin Bicêtre, AP-HP, Paris, France

    Raphaele Seror, Sophia Ascione, Rakiba Belkhir & Julien Henry

  5. Université Paris-Saclay, INSERM U1012, Le Kremlin Bicêtre, Paris, France

    Raphaele Seror

  6. Department of Radiation Oncology, Institut Curie, Paris, France

    Youlia Kirova

  7. Department of Pathology, GHU Paris Saclay, AP-HP, Paris, France

    Thierry Lazure

  8. Department of Pathology, GHU Paris-Nord - Saint-Louis, AP-HP, Paris, France

    Véronique Meignin

  9. Department of Hematology, GHU Paris Centre - Cochin-, AP-HP, Paris, France

    Justine Decroocq, Rudy Birsen, Lise Willems, Patricia Franchi, Bénédicte Deau-Fischer, Didier Bouscary & Marguerite Vignon

  10. Université Paris centre, Paris, France

    Rudy Birsen, Frédérique Larousserie, Nicolas Chapuis, Alexis Talbot & Didier Bouscary

  11. Laboratory of Hematology, GHU Paris Centre - Cochin-, AP-HP, Paris, France

    Nicolas Chapuis

  12. Unité de Génomique du Myélome, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France

    Laure Derrier, Luka Pavageau & Jill Corre

  13. Department of Hematology, Lille University Hospital, University of Lille, Canther INSERM UMR-S1277 and CNRS UMR9020, Lille, France

    Salomon Manier

Authors
  1. Barbara Burroni
    View author publications

    Search author on:PubMed Google Scholar

  2. Stéphanie Harel
    View author publications

    Search author on:PubMed Google Scholar

  3. Raphaele Seror
    View author publications

    Search author on:PubMed Google Scholar

  4. Sophia Ascione
    View author publications

    Search author on:PubMed Google Scholar

  5. Youlia Kirova
    View author publications

    Search author on:PubMed Google Scholar

  6. Diane Damotte
    View author publications

    Search author on:PubMed Google Scholar

  7. Rakiba Belkhir
    View author publications

    Search author on:PubMed Google Scholar

  8. Thierry Lazure
    View author publications

    Search author on:PubMed Google Scholar

  9. Véronique Meignin
    View author publications

    Search author on:PubMed Google Scholar

  10. Justine Decroocq
    View author publications

    Search author on:PubMed Google Scholar

  11. Virginie Audard
    View author publications

    Search author on:PubMed Google Scholar

  12. Rudy Birsen
    View author publications

    Search author on:PubMed Google Scholar

  13. Lise Willems
    View author publications

    Search author on:PubMed Google Scholar

  14. Frédérique Larousserie
    View author publications

    Search author on:PubMed Google Scholar

  15. Patricia Franchi
    View author publications

    Search author on:PubMed Google Scholar

  16. Yoan Velut
    View author publications

    Search author on:PubMed Google Scholar

  17. Nicolas Chapuis
    View author publications

    Search author on:PubMed Google Scholar

  18. Laure Derrier
    View author publications

    Search author on:PubMed Google Scholar

  19. Salomon Manier
    View author publications

    Search author on:PubMed Google Scholar

  20. Bénédicte Deau-Fischer
    View author publications

    Search author on:PubMed Google Scholar

  21. Julien Henry
    View author publications

    Search author on:PubMed Google Scholar

  22. Luka Pavageau
    View author publications

    Search author on:PubMed Google Scholar

  23. Alexis Talbot
    View author publications

    Search author on:PubMed Google Scholar

  24. Bruno Royer
    View author publications

    Search author on:PubMed Google Scholar

  25. Didier Bouscary
    View author publications

    Search author on:PubMed Google Scholar

  26. Bertrand Arnulf
    View author publications

    Search author on:PubMed Google Scholar

  27. Jill Corre
    View author publications

    Search author on:PubMed Google Scholar

  28. Marguerite Vignon
    View author publications

    Search author on:PubMed Google Scholar

Contributions

BB: designed and performed the research, analyzed data and wrote the paper. MV: designed and performed the research, analyzed data and wrote the paper. SH: performed the research, analyzed data. SA: performed the research, analyzed data. YK: performed the research, analyzed data. SM: performed the research, analyzed data. DD: performed the research, analyzed data and reviewed the paper. RS: performed the research, analyzed data and reviewed the paper. BA: performed the research, analyzed data and reviewed the paper. JC: performed the research, analyzed data and reviewed the paper. DB: performed the research, analyzed data and reviewed the paper. VA: performed the research. JH: performed the research. TL: performed the research. VM: performed the research. FL: performed the research. JD: performed the research. PF: performed the research. RBe: performed the research. RBi: performed the research. LW: performed the research. LD: performed the research. BD: performed the research. LP: performed the research. AT: performed the research. BR: performed the research. YV: performed statistical analyses. NC: contributed with analytical tools.

Corresponding author

Correspondence to Marguerite Vignon.

Ethics declarations

Ethics approval and consent to participate

All methods were performed in accordance with the relevant guidelines and regulations. Approval has been obtained from local ethics committee CERAPHP.5 reference 2020-02-02. An informed consent was obtained from all participants.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Burroni, B., Harel, S., Seror, R. et al. Molecular profiling and risk stratification in solitary bone plasmacytoma. Leukemia 39, 2568–2572 (2025). https://doi.org/10.1038/s41375-025-02699-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41375-025-02699-z

Search

Advanced search

Quick links